Over-colonization and subsequent inflammation triggered by Cutibacterium acnes is the primary factor in the pathogenesis of acne vulgaris, a prevalent skin condition among adolescents. Gyeongsang National University has discovered and characterized new antimicrobial peptides (AMPs) as candidates for the treatment of acne vulgaris.
Hangzhou Bio-Creativity Pharma-Tech Co. Ltd. has disclosed phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitors reported to be useful for the treatment of atopic dermatitis.
Kexing Biopharm Co. Ltd. has outlined progress in its cachexia and autoimmune pipelines, built upon its Kx-Body antibody technology platform and Kx-Fusion fusion protein technology platform.
Researchers from Tel Aviv Sourasky Medical Center presented data from a study that aimed to investigate the genetic mechanisms underlying yellow nail syndrome (YNS), a rare disorder characterized by three features, namely yellow dystrophic nails, lymphedema and chronic lung disease.
A recent study published in Science Translational Medicine has examined a new approach to address inflammatory skin diseases, such as dermatitis and rosacea, by focusing on a specific glutamate receptor in mast cells.
Gilead Sciences Inc. and Leo Pharma A/S have established a strategic partnership to accelerate the development and commercialization of Leo’s small-molecule oral STAT6 programs for the treatment of inflammatory diseases.
Nimbus Therapeutics LLC has disclosed 15-hydroxyprostaglandin dehydrogenase inhibitors reported to be useful for the treatment of alopecia, muscle atrophy and more.
Kaken Pharmaceutical Co. Ltd. and Johnson & Johnson (J&J) have entered into a license agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), developed by Kaken.
Deepcure Inc. has discovered potent, selective oral small-molecule inhibitors of STAT6. These next-generation STAT6 inhibitors have demonstrated promising oral bioavailability, cell permeability and metabolic stability, and do not target STAT6 for degradation.
RSS
